4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Mycosis Fungoides by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 183 ongoing clinical trials involving Mycosis Fungoides
Of the 183 trials,59 trials are in Phase II
Furthermore, 46 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Mycosis Fungoides by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Mycosis Fungoides, an oncology indication. The largest number of ongoing clinical trials for Mycosis Fungoides is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Mycosis Fungoides-related drug trials.

National Cancer Institute US: The leading ongoing Mycosis Fungoides related clinical trial sponsor

National Cancer Institute US is the top sponsor for Mycosis Fungoides-related ongoing clinical trials.

Mayo Clinic, University of Texas MD Anderson Cancer Center, and City of Hope are among other notable clinical trial sponsors involved in Mycosis Fungoides. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Mycosis Fungoides

Brentuximab vedotin (Adcetris), Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone), and Mogamulizumab (Poteligeo) are among the key marketed drugs involving Mycosis Fungoides.

Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It functions via Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30L Receptor or Ki 1 Antigen or Lymphocyte Activation Antigen CD30 or CD30 or TNFRSF8) mechanism of action. It is formulated as a lyophilized powder for solution for intravenous route of administration. Mycosis Fungoides is marketed for the treatment of Mycosis Fungoides and several other indications including Cutaneous T-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Mycosis Fungoides, Peripheral T-Cell Lymphomas (PTCL). Brentuximab vedotin was first approved in 2011 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several pharma giants including Takeda Pharmaceutical Co Ltd, and Seagen Inc.

Methylprednisolone (Solu-Medrol, Depo-Medrol, Medrol, Medrate, Depo-Medrate, Medrol Acetate, Solu-Medrone, Solu-Moderin, Depo-Medrone, Methylprednisolone Sodium Succinate, Promedrol, Medrol A, Medroxyprogesterone Acetate Greenstone) is a glucocorticoid, anti-inflammatory agent. It functions via Glucocorticoid Receptor (GR or Nuclear Receptor Subfamily 3 Group C Member 1 or NR3C1) Agonist mechanism of action. It is formulated as tablets for oral administration, lyophilized powder for solution, suspension and solution for intravenous, intramuscular, intraarticular, intralesional, intrasynovial route of administration. It is also formulated as enema for rectal administration and as ointment for topical administration. Methylprednisolone is marketed for the treatment of Mycosis Fungoides and several other indications including Multiple Sclerosis, Arthritis, Osteoarthritis, Asthma, Allergic Rhinitis, Lupus Nephritis, Hypoglycemia, Alopecia, Seborrhea, Liver Cirrhosis, Proteinuria. Methylprednisolone was first approved in 1957 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Pfizer Inc and its subsidiaries.